2010 Annual Scientific Meeting and Exposition 2010 Annual ...

More documents

Recommendations

Info

Faculty Disclosure Listing continuedLance K. Stell, PhDAdvisor/Consultant: MedImpact.Neil J. Stone, MDOther: Educational Committee for The National Lipid Association.Thomas P. Stossel, MDRoyalties: Velico, Inc. Advisor/Consultant: Pfizer. Trustee, BoardMember, Committee Member: Velico, Inc., Critical Biologics.Patrick J. Strollo, Jr., MDGrant/Research Support: ResMed. Philips Respironics.S<strong>and</strong>ra J. Taler, MDSecretary, ASH Board of Directors.Addison A. Taylor, MD, PhDGrant/Research Support: Merck, Novartis, Forest, Abbott, Sanofi-Aventis, Bristol-Meyers-Squibb, Pfizer, NIH. Member, ASH Board ofDirectors.Stephen C. Textor, MDTrustee, Board Member, Committee Member: American Society ofNephrology Associate Editor.Rhian M. Touyz, MD, PhDGrant/Research Support: Pfizer, AstraZeneca.Raymond R. Townsend, MDAdvisor/Consultant: NicOx, Novartis, Roche, GlaxoSmithKline.Speakers’ Bureau/Speaking/Teaching: ASN, ASH, NKF. Grant/ResearchSupport: National Institutes of Health/NIDDK.P. Roy Vagelos, MDEmployment Income/Salary: Regeneron Pharma., Theravance.Trustee, Board Member, Committee Member: Regeneron Pharma.,Theravance. Ownership Interest: Regeneron, Theravance.Hector O. Ventura, MDSpeakers’ Bureau/Speaking/Teaching: Actelion, Gilead.Charalambos Vlachopoulos, MDI have no relationships or affiliations to disclose.Hongyu Wang, MD, PhDI have no relationships or affiliations to disclose.Michael A. Weber, MDAdvisor/Consultant: Bistol-Myers Squibb, Forest, Gilead, Novartis,Daiichi-Sankyo, Boehringer-Ingelheim, Takeda. Speakers’ Bureau/Speaking/Teaching: Sanofi-Aventis, Novartis, Daiichi-Sankyo, Boehringer-Ingelheim,GlaxoSmithKline, Forest. Member, ASH Board ofDirectors. Editor-in-Chief, JCH.Myron H. Weinberger, MDEmployment Income/Salary: Editor-in-Chief, JASH. Advisor/Consultant:DSI, Merck, Novartis. Speakers’ Bureau/Speaking/Teaching: SCS,IntraMed. Member, ASH Board of Directors.Howard Weintraub, MDSpeakers’ Bureau/Speaking/Teaching: Takeda, AstraZeneca, Gilead,Daiichi-Sankyo, Novartis.William B. White, MDAdvisor/Consultant: Astellas, Novartis, Takeda, NicOx. Grant/ResearchSupport: Novartis, NIH. Member, ASH Board of Directors.168
Faculty Disclosure Listing continuedChristopher S. Wilcox, MD, PhDAdvisor/Consultant: Mitos.Peter F. Wilson, MDI have no relationships or affiliations to disclose.Gordon H. Williams, MDAdvisor/Consultant: Pfizer.Clyde W. Yancy, MDI have no relationships or affiliations to disclose.Steven A. Yarows, MDAdvisor/Consultant: HoMedics, Inc. Grant/Research Support: Daiichi-Sankyo,Forest, Novartis. Speakers’ Bureau/Speaking/Teaching:Boehringer-Ingelheim, Novartis, Forest, Pfizer, Bristol-Myers Squibb.169
Page 1 and 2:
American Society of Hypertension201
Page 3 and 4:
Valturna offers bothsuperior BP eff
Page 5 and 6:
Figure 2: Probability of Achieving
Page 7 and 8:
potential for other drugs acting on
Page 9 and 10:
aliskiren arms were about one-third
Page 11 and 12:
As with other drugs that block angi
Page 13:
American Society of Hypertension201
Page 18:
Program Color KeyThe pages of this
Page 21 and 22:
General InformationThis program boo
Page 23 and 24:
General Information continuedHilton
Page 25 and 26:
General Information continuedASH Sc
Page 27 and 28:
General Information continuedASH Hy
Page 29 and 30:
2010 ASH Corporate MembersBoehringe
Page 31 and 32:
ASH Leadership2009-2010 Board of Di
Page 33 and 34:
Special LectureMonday, May 3, 2010,
Page 35 and 36:
Special LectureMonday, May 3, 2010,
Page 37 and 38:
2010 Abstract Reviewers continuedEr
Page 39 and 40:
Visit TEKTURNA at Booth 1100.and/or
Page 41 and 42:
5.5 HyperkalemiaIncreases in serum
Page 43 and 44:
with Pgp substrates or weak to mode
Page 45 and 46:
ASH Program at a GlanceSaturday, Ma
Page 47 and 48:
ASH Program at a GlanceMonday, May
Page 49 and 50:
Poster Category PresentationPosters
Page 51 and 52:
2010 ASH Faculty continuedJeffrey R
Page 53 and 54:
2010 ASH Faculty continuedAndrew Wh
Page 55 and 56:
2010American Societyof Hypertension
Page 57 and 58:
Saturday Afternoon MAY 1PostersPost
Page 59 and 60:
Saturday Afternoon MAY 1Sessions3:3
Page 61 and 62:
Saturday Afternoon MAY 1Sessions3:3
Page 63 and 64:
Sunday Morning MAY 2Satellite Sympo
Page 65 and 66:
Sunday Morning MAY 2Sessions contin
Page 67 and 68:
Sunday Morning MAY 2Sessions8:00 AM
Page 69 and 70:
Sunday Morning MAY 2Sessions10:00 A
Page 71 and 72:
Sunday Morning MAY 2Sessions10:00 A
Page 73 and 74:
Sunday Afternoon MAY 2Sessions3:30
Page 75 and 76:
Sunday Afternoon MAY 2Sessions3:30
Page 77 and 78:
Sunday Afternoon MAY 2Special Sessi
Page 79 and 80:
Sunday Evening MAY 2Sessions6:00 PM
Page 81 and 82:
Sunday Evening MAY 2Sessions6:00 PM
Page 83 and 84:
Monday Morning MAY 3Satellite Sympo
Page 85 and 86:
Monday Morning MAY 3Sessions8:00 AM
Page 87 and 88:
Monday Morning Afternoon MAY 21 3Po
Page 89 and 90:
Monday Morning MAY 3Sessions10:00 A
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Monday Evening May 3Satellite Sympo
Page 97 and 98:
Tuesday Morning May 48:45 AM LB-OR-
Page 99 and 100:
Tuesday Morning May 4Sessions8:00 A
Page 101 and 102:
Tuesday Morning MAY 4ASH Membership
Page 103 and 104:
Tuesday Morning MAY 4Sessions10:55
Page 105 and 106:
2010American Societyof Hypertension
Page 107 and 108:
Saturday Afternoon MAY 1Posters3:00
Page 109 and 110:
Saturday Afternoon MAY 1PostersPO-2
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120: Saturday Afternoon MAY 1PostersPO-8
Page 125 and 126: Sunday Morning MAY 2PostersPosters
Page 127 and 128: Sunday Morning MAY 2Posters9:00 AM
Page 129 and 130: Sunday Morning MAY 2PostersPO-123:
Page 143 and 144: Monday Morning Afternoon MAY 21 3Po
Page 161 and 162: Monday Morning Afternoon May 213Pos
Page 163 and 164: Faculty Disclosure ListingGail Adle
Page 165 and 166: Faculty Disclosure Listing continue
Page 167 and 168: Faculty Disclosure Listing continue
Page 169: Faculty Disclosure Listing continue
Page 173 and 174: you to attend thethe Innovations Th
Page 175 and 176: 5.5 HyperkalemiaIncreases in serum
Page 177 and 178: with Pgp substrates or weak to mode
Page 179 and 180: Valturna (aliskiren and valsartan,
Page 181 and 182: 4 CONTRAINDICATIONSNone.5 WARNINGS
Page 183 and 184: een reported. In a 4-day trial of v
Page 185 and 186: 7 DRUG INTERACTIONSNo drug interact
Page 187 and 188: 8.5 Geriatric UseIn 8.5the Geriatri
Page 189 and 190: 2010 ASH ExhibitorsASH Hypertension
Page 191 and 192: ASH Hypertension Resource CenterHil
Page 193 and 194: 2010 ASH Exhibitors continuedCVRx I
Page 195 and 196: 2010 ASH Exhibitors continuedIntern
Page 197 and 198: 2010 ASH Exhibitors continuedNature
Page 199 and 200: 2010 ASH Exhibitors continuedRESPeR
Page 201 and 202: Author IndexAAbaunza, Ricardo, 122A
Page 203 and 204: Author IndexCastellano, Maurizio, 1
Page 205 and 206: Author IndexGuarneri, Marco, 146Guo
Page 207 and 208: Author IndexLekakis, John, 118, 122
Page 209 and 210: Author IndexPittaras, Andreas, 149P
Page 211 and 212: Author IndexTello, Susana, 109, 135
Page 213 and 214: Hilton New York Floor PlansSecond F
Page 215 and 216: Hilton New York Floor PlansFourth F
Page 218: Are You 1in 3?Get the facts. Know y
show all

2010 Annual Scientific Meeting and Exposition 2010 Annual ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?